recent
year
increas
level
resist
four
fdaapprov
antiinfluenza
viru
drug
describ
vaccin
manufactur
experienc
demand
exceed
capac
situat
underlin
urgent
need
novel
antivir
well
innov
vaccin
product
prepar
next
influenza
epidem
report
develop
cellbas
highthroughput
screen
use
identif
compound
modul
influenza
viru
growth
either
neg
posit
screen
librari
compound
known
biolog
activ
identifi
distinct
group
inhibitor
enhanc
target
sodium
channel
protein
kinas
c
pkc
confirm
result
viral
growth
assay
find
treatment
sodium
channel
open
pkc
inhibitor
significantli
reduc
viral
replic
contrast
inhibit
sodium
channel
activ
pkc
lead
enhanc
viru
product
tissu
cultur
diametr
oppos
effect
strongli
support
role
pkc
activ
regul
na
current
influenza
viru
replic
may
serv
target
antivir
drug
furthermor
rais
possibl
compound
result
increas
viral
titer
may
benefici
boost
product
tissu
culturegrown
influenza
vaccin
influenza
virus
envelop
rna
virus
belong
famili
orthomyxovirida
pales
shaw
influenza
b
virus
consid
major
human
pathogen
normal
season
caus
million
case
sever
ill
death
worldwid
influenza
virus
also
caus
pandem
occur
outbreak
result
high
mortal
rate
lack
preexist
immun
new
viru
strain
sinc
emerg
highli
pathogen
avian
influenza
viru
late
claa
et
al
concern
may
next
pandem
viru
spark
renew
interest
develop
antiinfluenza
viru
drug
current
four
us
food
drug
administr
fda
approv
drug
avail
treatment
prevent
influenza
adamantan
amantadin
rimantadin
block
ion
channel
viru
prevent
releas
viral
genom
host
cell
pinto
lamb
wharton
et
al
drug
effect
use
prophylact
administ
within
hour
infect
effect
influenza
b
virus
unfortun
develop
widespread
resist
preclud
use
adamantan
recent
influenza
season
bright
et
al
isol
influenza
viru
shown
resist
drug
due
mutat
cheung
et
al
prefer
treatment
influenza
viru
infect
use
neuraminidas
inhibitor
oseltamivir
zanamivir
garman
laver
target
neuraminidas
compound
prevent
releas
viru
infect
cell
halt
spread
viru
part
pandem
prepared
plan
world
health
organ
advis
suppli
neuraminidas
inhibitor
stockpil
alway
advantag
least
two
antivir
drug
aim
differ
target
avail
due
possibl
emerg
resist
viru
strain
fact
influenza
season
northern
hemispher
shown
mark
increas
number
isol
resist
oseltamivir
concern
also
rais
regard
oseltamivirresist
influenza
virus
isol
patient
southeast
asia
le
et
al
vaccin
far
best
mean
prevent
infect
least
minim
sever
diseas
base
knowledg
current
circul
influenza
viru
strain
make
annual
decis
viru
strain
includ
influenza
vaccin
follow
season
manufactur
therefor
rel
short
time
period
gener
new
vaccin
stock
combin
increas
demand
popul
sometim
lead
shortag
vaccin
virus
current
grown
embryon
chicken
egg
gener
support
high
level
viru
growth
howev
use
egg
certain
limit
vaccin
product
easili
scale
short
notic
would
requir
pandem
due
relianc
continu
suppli
embryon
egg
furthermor
pandem
viru
avian
origin
may
lethal
egg
occur
prepar
vaccin
candid
takada
et
al
avian
viru
would
like
also
affect
poultri
industri
egg
suppli
may
greatli
reduc
effort
avoid
problem
vaccin
manufactur
establish
tissu
cultur
system
growth
influenza
viru
vaccin
oxford
et
al
romanova
et
al
tree
et
al
major
disadvantag
wild
type
human
influenza
viru
strain
often
show
optim
growth
properti
cultur
system
result
lower
vaccin
yield
conclus
urgent
need
develop
new
antivir
drug
also
improv
tissu
culturebas
vaccin
product
prepar
futur
influenza
epidem
pandem
mind
design
cellbas
highthroughput
assay
allow
us
screen
small
molecular
weight
compound
modul
influenza
viru
growth
initi
screen
compound
known
biolog
activ
identifi
compound
neg
regul
influenza
viru
replic
may
potenti
antivir
drug
also
identifi
compound
enhanc
influenza
viru
growth
propos
may
use
tool
boost
replic
influenza
viru
vaccin
candid
tissu
cultur
human
alveolar
basal
epitheli
cell
african
green
monkey
kidney
vero
cell
chicken
embryo
fibroblast
cell
madindarbi
canin
kidney
mdck
cell
obtain
american
type
cultur
collect
atcc
manassa
va
cell
vero
cell
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
corp
carlsbad
ca
supplement
fetal
bovin
serum
fb
hyclon
south
logan
ut
uml
penicillin
g
sodium
streptomycin
sulfat
invitrogen
corp
carlsbad
ca
mdck
cell
cultur
minimum
essenti
medium
mem
invitrogen
corp
carlsbad
ca
supplement
fb
mm
lglutamin
invitrogen
corp
carlsbad
ca
uml
penicillin
g
sodium
mgl
streptomycin
sulfat
nahco
invitrogen
corp
carlsbad
ca
influenza
viru
influenza
viru
grown
mdck
cell
mempostinfect
medium
mem
supplement
bovin
serum
albumin
bsa
fb
mm
lglutamin
uml
penicillin
g
sodium
streptomycin
sulfat
nahco
virus
titer
standard
plaqu
assay
mdck
cell
vesicular
stomat
viru
express
green
fluoresc
protein
vsvgfp
kindli
provid
john
hiscott
mcgill
univers
montreal
canada
grown
titer
vero
cell
newcastl
diseas
viru
strain
grown
embryon
hen
egg
titer
cell
human
isol
influenza
amoscow
virus
grown
embryon
hen
egg
titer
mdck
cell
recombin
influenza
viru
reassort
express
low
virul
hemagglutinin
ha
neuraminidas
na
influenza
viru
refer
studi
rescu
use
revers
genet
fodor
et
al
ha
influenza
viru
mutat
remov
multibas
cleavag
site
associ
high
pathogen
chicken
senn
et
al
briefli
express
plasmid
ppol
plasmid
ha
na
gene
influenza
viru
cotransfect
cell
togeth
ambisens
pdz
plasmid
pa
np
ns
segment
influenza
viru
supernat
transfer
hour
later
embryon
hen
egg
allow
recombin
viru
propag
egggrown
viru
stock
sequenc
titer
mdck
cell
construct
influenza
minigenom
report
firefli
luciferas
open
read
frame
promega
corp
madison
wi
amplifi
pcr
end
crna
promot
influenza
viru
np
segment
incorpor
either
end
neumann
hobom
product
insert
ppoli
vector
pleschka
et
al
luciferas
gene
neg
sens
prestwick
chemic
librari
compound
prestwick
chemic
inc
washington
dc
nind
custom
collect
compound
nation
institut
neurolog
disord
stroke
bethesda
md
biomol
known
librari
compound
biomol
plymouth
meet
pa
provid
institut
chemistri
cell
biolog
iccb
nation
screen
laboratori
region
center
excel
biodefens
emerg
infecti
diseas
nsrb
harvard
univers
boston
compound
dissolv
dmso
mgml
prestwick
librari
mgml
librari
mm
librari
secondari
analys
purchas
biomol
plymouth
meet
pa
phenamil
phorbol
pma
mezerein
rottlerin
staurosporin
ouabain
lanatosid
c
purchas
sigmaaldrich
stloui
mo
compound
dissolv
either
h
dimethyl
sulfoxid
dmso
stock
concentr
final
concentr
dmso
cultur
medium
exceed
assay
perform
duplic
use
solid
white
tissu
cultur
treat
plate
corn
life
scienc
lowel
cell
cultur
confluenc
trypsin
trypsinedta
invitrogen
corp
carlsbad
ca
resuspend
phenol
redfre
dmem
growth
medium
supplement
fb
cellsml
transfect
done
bulk
well
ng
report
dilut
optimem
invitrogen
corp
carlsbad
ca
mix
optimem
contain
invitrogen
corp
carlsbad
ca
transfect
mix
incub
min
ad
resuspend
cell
approxim
cell
medium
also
includ
scriptaid
biomol
plymouth
meet
pa
sigmaaldrich
stloui
mo
ad
enhanc
reproduc
assay
hellebrek
et
al
mix
cell
report
dna
transfer
plate
use
matrix
wellmat
plate
filler
load
plate
subsequ
centrifug
rpm
min
ensur
equal
distribut
cell
within
well
cell
incub
hour
co
humid
addit
nl
compound
epson
compound
transfer
robot
epson
america
inc
long
beach
ca
cell
incub
hour
infect
influenza
viru
directli
medium
moi
viru
ad
automat
plate
use
matrix
wellmat
plate
filler
plate
subsequ
centrifug
rpm
min
plate
also
contain
mockinfect
cell
use
posit
control
cell
infect
untreat
use
neg
control
two
approv
class
influenza
antivir
drug
could
use
posit
control
screen
influenza
viru
resist
amantadin
ii
assay
detect
multicycl
replic
necessari
see
effect
oseltamivir
target
viru
releas
infect
allow
proceed
hour
co
humid
time
medium
well
remov
plate
equilibr
room
temperatur
least
min
matrix
wellmat
plate
filler
use
add
brightgloluciferas
reagent
promega
corp
madison
wi
well
automat
follow
min
centrifug
rpm
luminesc
measur
swell
plate
reader
perkin
elmer
inc
waltham
elimin
cytotox
compound
appear
fals
posit
counter
screen
perform
parallel
consist
cell
transfect
seed
densiti
cell
per
well
plate
remaind
assay
perform
describ
except
cell
infect
evalu
ht
assay
robust
plate
contain
compound
run
separ
two
differ
day
statist
paramet
determin
follow
z
mean
signal
neg
control
infect
cell
standard
deviat
neg
control
mean
signal
posit
control
mock
infect
cell
standard
deviat
posit
control
percent
coeffici
variat
cv
signaltobackground
ratio
sb
signaltonois
ratio
sn
ghosh
et
al
zhang
et
al
data
influenza
ht
assay
counter
screen
analyz
microsoft
offic
excel
averag
neg
control
plate
set
luminesc
percent
luminesc
compoundcontain
well
determin
relat
intern
control
averag
percent
luminesc
duplic
screen
calcul
compound
classifi
strong
medium
inhibitor
base
reduct
luminesc
respect
compound
lead
increas
luminesc
consid
enhanc
least
fold
induct
neg
control
ht
data
compar
correspond
data
counter
screen
reduct
luminesc
greater
counter
screen
consid
caus
cytotox
therefor
compound
defin
fals
posit
elimin
analysi
threshold
decreas
case
compound
caus
reduct
luminesc
signal
influenza
ht
assay
celltit
aq
ueou
one
solut
cell
prolifer
assay
refer
mt
assay
studi
promega
corp
madison
wi
use
detect
cell
viabil
accord
specif
manufactur
briefli
cell
seed
plate
corn
life
scienc
lowel
cell
per
well
allow
incub
hour
co
incub
medium
aspir
replac
fresh
dmem
contain
compound
variou
concentr
follow
hour
incub
mt
solut
ad
well
left
incub
hour
measur
absorb
nm
use
beckman
coulter
dtx
plate
reader
beckman
coulter
inc
fullerton
ca
cell
seed
plate
cell
per
well
incub
hour
co
cell
wash
phosphat
buffer
salin
pb
invitrogen
corp
carlsbad
ca
medium
replac
dmem
supplement
bsa
fb
uml
penicillin
g
sodium
streptomycin
sulfat
contain
compound
interest
compound
enhanc
viral
replic
use
potent
concentr
nm
phenamil
nm
mezerein
nm
pma
compound
inhibit
viral
replic
use
potent
nontox
concentr
rottlerin
cardioact
glycosid
test
concentr
maintain
least
cell
viabil
nm
ouabain
nm
lanatosid
c
cell
incub
compoundcontain
media
hour
prior
infect
test
respons
influenza
viru
viru
enhanc
infect
done
multipl
wherea
multipl
use
test
respons
influenza
viru
inhibitor
human
isol
influenza
virus
infect
done
moi
test
enhanc
influenza
byamagata
viru
infect
done
multipl
test
inhibitor
multipl
test
enhanc
compound
absent
hour
incub
viru
present
postinfect
medium
dmem
supplement
bsa
fb
uml
penicillin
g
sodium
streptomycin
sulfat
infect
influenza
b
viru
human
influenza
viru
isol
viru
postinfect
medium
also
contain
tpcktreat
trypsin
sigmaaldrich
stloui
mo
infect
cell
incub
except
influenza
b
viru
infect
cell
incub
viral
titer
virus
determin
variou
time
post
infect
standard
plaqu
assay
mdck
cell
test
effect
cardioact
glycosid
growth
ndv
vsvgfp
infect
perform
moi
viral
titer
determin
hour
post
infect
standard
plaqu
assay
vero
cell
vsvgfp
cell
ndv
plaqu
visual
immunostain
antinp
antibodi
matrosovich
et
al
colorimetr
assay
r
system
inc
minneapoli
mn
use
detect
whether
compound
proor
antiapoptot
effect
cell
seed
tissu
cultur
treat
dish
corn
life
scienc
lowel
cell
per
dish
allow
incub
hour
co
incub
medium
aspir
cell
wash
pb
fresh
dmem
postinfect
medium
ad
contain
compound
concentr
use
viral
infect
posit
control
induct
apoptosi
cell
treat
staurosporin
concentr
cell
incub
hour
co
subsequ
harvest
wash
twice
pb
lyse
incub
devdafc
substrat
addit
hour
co
measur
fluoresc
nm
use
versa
fluor
fluoromet
biorad
hercul
ca
develop
cellbas
ht
assay
identif
small
molecul
neg
posit
affect
influenza
viru
replic
influenza
minigenom
design
encod
firefli
luciferas
neg
sens
crna
promot
influenza
viru
np
segment
construct
clone
plasmid
flank
human
rna
polymeras
promot
hepat
viru
hdv
ribozym
fig
upon
transfect
report
human
lung
epitheli
cell
rna
polymeras
transcript
gener
rna
segment
mimic
viral
rna
cell
subsequ
infect
influenza
viru
segment
recogn
viral
polymeras
result
product
firefli
luciferas
mrna
luciferas
activ
therefor
serv
measur
influenza
viru
replic
decreas
increas
signal
observ
presenc
specif
compound
indic
inhibitori
enhanc
activ
respect
due
fact
high
multipl
infect
provid
greatest
reproduc
assay
like
detect
compound
act
step
includ
translat
multicycl
format
would
necessari
detect
inhibitor
later
stage
assembl
bud
releas
respect
assay
differ
cellbas
ht
assay
influenza
viru
reli
virusinduc
cytopath
effect
cpe
readout
use
low
multipl
infect
noah
et
al
note
assay
perform
madindarbi
canin
kidney
mdck
cell
display
signific
cpe
respons
influenza
viru
infect
assay
perform
cell
biolog
relev
cell
type
influenza
viru
infect
assay
initi
optim
format
valid
use
highthroughput
screen
confirm
demonstr
z
factor
zhang
et
al
screen
purpos
assay
adapt
format
tabl
show
statist
paramet
use
evalu
robust
assay
format
z
factor
determin
two
separ
run
discrep
z
factor
valu
determin
plate
plate
explain
edg
effect
higher
variabl
miniatur
format
howev
format
meet
requir
highthroughput
screen
assay
z
factor
valu
z
consid
excel
use
ht
larger
valu
higher
data
qualiti
zhang
et
al
addit
paramet
verifi
assay
robust
coeffici
variat
cv
signaltobackground
ratio
sb
signaltonois
ratio
sn
sn
ratio
slightli
ratio
anoth
report
ht
influenza
viru
sn
noah
et
al
reflect
higher
signal
deviat
assay
nonetheless
still
better
compar
ht
assay
sar
coronaviru
sn
recent
number
cellbas
ht
assay
develop
screen
compound
differ
virus
sb
ratio
assay
strongli
ht
assay
report
influenza
viru
sb
noah
et
al
sar
coronaviru
sb
human
immunodefici
viru
sb
blair
et
al
hepat
c
viru
hcv
sb
zuck
et
al
dengu
viru
sb
chu
yang
high
sb
ratio
addit
cv
prove
suitabl
assay
use
highthroughput
screen
subsequ
pilot
screen
conduct
harvard
institut
cell
chemic
biolog
iccb
librari
plate
compound
test
duplic
screen
librari
plate
contain
uncharacter
compound
found
one
strong
inhibitor
strong
inhibitor
detect
screen
compound
known
bioactiv
overal
strong
inhibitor
identifi
equal
hit
rate
rate
rel
high
due
fact
cytotox
compound
includ
hit
order
elimin
fals
posit
ran
counter
screen
parallel
describ
section
futur
screen
part
initi
studi
screen
three
compound
librari
consist
collect
nind
prestwick
biomol
total
small
molecul
compound
known
biolog
activ
ie
cellular
target
known
facilit
downstream
analys
cell
transfect
report
plasmid
bulk
plate
solid
white
plate
incub
overnight
six
hour
prior
infect
nl
test
compound
librarydefin
concentr
ad
automat
well
duplic
influenza
viru
ad
media
multipl
infect
moi
infect
allow
proceed
hour
ad
luciferas
substrat
luminesc
measur
compar
control
well
receiv
compound
well
result
counter
screen
elimin
fals
posit
screen
compound
identifi
strong
inhibitor
luciferas
signal
reduc
addit
compound
found
reduc
signal
compound
increas
luminesc
least
twofold
fig
compound
present
either
two
librari
identifi
hit
independ
two
three
time
therefor
total
identifi
uniqu
strong
inhibitor
uniqu
moder
inhibitor
enhanc
tabl
show
function
class
hit
compound
identifi
inhibitor
ht
inhibitor
compound
interfer
dna
anoth
group
consist
antibiot
antifung
antiparasit
drug
roughli
inhibitor
target
differ
cellular
kinas
like
protein
kinas
protein
kinas
c
receptor
tyrosin
kinas
inhibitori
compound
na
k
atpas
pump
inhibitor
ouabain
lanatosid
c
digoxin
strophanthidin
known
cardioact
glycosid
initi
effect
compound
sodium
channel
open
also
identifi
inhibitor
rais
intracellular
na
concentr
interestingli
one
compound
result
increas
luciferas
signal
phenamil
amilorid
analogu
act
sodium
channel
inhibitor
oppos
effect
compound
contrast
effect
sodium
channel
indic
influenza
viru
sensit
chang
intracellular
ion
concentr
may
way
modul
influenza
viru
replic
support
report
influenza
viru
inhibit
amiloridesensit
sodium
channel
respiratori
epithelium
chen
et
al
kunzelmann
et
al
amongst
group
inhibitori
compound
also
found
sever
protein
kinas
c
pkc
inhibitor
strongest
rottlerin
pkc
inhibitor
previous
shown
inhibit
influenza
viru
kurokawa
et
al
root
et
al
sieczkarski
et
al
furthermor
evid
pkc
activ
involv
regul
epitheli
sodium
channel
booth
stockand
kunzelmann
et
al
stockand
et
al
yamagata
et
al
investig
effect
influenza
viru
growth
therefor
focus
compound
target
either
sodium
ion
transport
pkc
highthroughput
assay
reveal
sodium
channel
open
pkc
inhibitor
rottlerin
potenti
influenza
viru
inhibitor
order
confirm
find
specif
first
determin
cytotox
profil
compound
cell
seed
plate
treat
increas
concentr
rottlerin
hour
perform
mt
assay
determin
cell
viabil
cc
concentr
cytotox
determin
concentr
found
nontox
cc
rottlerin
determin
concentr
decreas
cell
viabil
experi
rottlerin
perform
use
maximum
concentr
determin
ic
half
maxim
inhibitori
concentr
inhibitor
cell
infect
hour
influenza
viru
moi
presenc
increas
compound
concentr
viral
titer
determin
plaqu
assay
ic
determin
result
select
index
si
cc
ic
classifi
sodium
channel
open
weak
inhibitor
ic
rottlerin
determin
nm
si
pkc
inhibitor
consid
moder
inhibitor
tabl
summar
cc
ic
si
valu
inhibitor
subsequ
compound
test
highest
nontox
concentr
inhibitori
activ
influenza
viru
influenza
viru
fig
presenc
reduct
titer
influenza
viru
compar
untreat
control
growth
influenza
byamagata
viru
reduc
compar
untreat
control
titer
influenza
awsn
viru
influenza
viru
significantli
reduc
respect
presenc
rottlerin
identif
enhanc
perform
best
multicycl
replic
condit
limit
ht
assay
perform
high
multipl
infect
therefor
probabl
allow
detect
strong
enhanc
furthermor
compound
enhanc
activ
may
mark
fals
neg
concentr
screen
perform
cytotox
although
screen
pkc
activ
pma
identifi
enhanc
probabl
concentr
pma
use
screen
toxic
nevertheless
decid
investig
effect
pma
anoth
pkc
activ
mezerein
due
link
pkc
activ
sodium
channel
regul
fact
pkc
inhibitor
downregul
influenza
viru
growth
sodium
channel
inhibitor
addit
phenamil
identifi
screen
potenti
enhanc
also
examin
effect
relat
sodium
channel
inhibitor
dichlorobenzamil
cell
infect
influenza
viru
low
multipl
presenc
increas
concentr
compound
order
find
effect
concentr
data
shown
multicycl
growth
assay
influenza
viru
perform
presenc
nm
phenamil
nm
pma
nm
mezerein
fig
growth
influenza
viru
significantli
enhanc
presenc
sodium
channel
inhibitor
compar
untreat
control
viral
titer
increas
fold
presenc
nm
fold
presenc
phenamil
hour
post
infect
fig
presenc
pkc
activ
titer
influenza
viru
increas
fold
nm
mezerein
fold
nm
pma
compar
untreat
cell
hour
post
infect
fig
also
examin
enhanc
effect
compound
replic
influenza
viru
fig
presenc
nm
viral
titer
increas
fold
hour
post
infect
compar
untreat
cell
mezerein
viral
growth
enhanc
seen
much
earlier
fold
increas
hour
post
infect
therefor
growth
influenza
b
virus
enhanc
addit
sodium
channel
inhibitor
pkc
activ
also
examin
whether
growthenhanc
effect
compound
could
observ
human
isol
influenza
viru
adapt
cell
cultur
purpos
compar
growth
influenza
virus
absenc
presenc
mezerein
virus
grow
poorli
cell
observ
signific
increas
maximum
viral
titer
presenc
mezerein
compar
untreat
cell
fig
b
suggest
abil
compound
boost
viru
replic
properti
extend
mani
differ
influenza
viru
strain
benefici
use
product
influenza
vaccin
chang
everi
year
current
egggrown
vaccin
seed
strain
influenza
virus
reassort
virus
contain
ha
na
gene
vaccin
viru
background
influenza
viru
done
obtain
high
titer
egg
avoid
need
adapt
new
viru
strain
strategi
use
influenza
vaccin
approv
fda
addit
multibas
cleavag
site
present
ha
associ
high
pathogen
chicken
remov
subbarao
et
al
treanor
et
al
examin
growth
properti
vaccin
viru
cell
treat
found
could
significantli
increas
titer
fold
compar
untreat
cell
fig
also
observ
signific
increas
viral
titer
presenc
mezerein
fold
fold
respect
influenza
viru
grown
vero
cell
one
approv
cell
line
vaccin
product
data
shown
compound
act
cellular
pathway
differ
cell
type
like
observ
optim
compound
modif
may
requir
achiev
best
possibl
effect
address
question
whether
correl
viral
inhibitori
enhanc
activ
compound
abil
induc
inhibit
apoptosi
monitor
activ
indic
apoptosi
induct
mimic
condit
cell
time
infect
cell
incub
compound
hour
staurosporin
use
posit
control
induc
apoptosi
phenamil
enhanc
influenza
viru
growth
show
slight
induct
fold
apoptosi
time
period
wherea
compound
display
signific
increas
decreas
fluoresc
compar
untreat
cell
indic
absenc
proapoptot
antiapoptot
activ
data
shown
develop
stage
activ
drug
candid
often
modul
make
small
chang
structur
compound
compar
effect
versu
abil
enhanc
influenza
viru
growth
fig
compound
boost
influenza
viru
replic
obtain
untreat
control
simpl
chang
chlorid
posit
benzyl
group
posit
make
time
less
effici
na
k
atpas
pump
inhibitor
ouabain
lanatosid
c
strophanthidin
digoxin
identifi
potenti
influenza
viru
inhibitor
ht
cardioact
glycosid
use
treatment
congest
heart
failur
cardiac
arrhythmia
also
shown
inhibit
replic
herp
simplex
viru
hsv
dodson
et
al
vaccinia
viru
deng
et
al
murin
leukemia
viru
mulv
tomita
kuwata
sendai
viru
nagai
et
al
confirm
initi
find
examin
abil
ouabain
lanatosid
c
inhibit
influenza
viru
replic
cc
ouabain
lanatosid
c
cell
determin
nm
nm
respect
data
shown
viral
replic
assay
cc
use
compound
cell
infect
moi
influenza
viru
presenc
nm
ouabain
nm
lanatosid
c
hour
post
infect
viral
titer
found
decreas
ouabain
treatment
lanatosid
c
treatment
compar
untreat
control
fig
compound
also
shown
inhibit
replic
virus
investig
whether
effect
influenza
virus
extend
rna
virus
found
ouabain
lanatosid
c
significantli
inhibit
replic
newcastl
diseas
viru
ndv
fig
vesicular
stomat
viru
vsv
fig
result
indic
na
k
atpas
pump
inhibitor
inhibit
multipl
member
rna
dna
viru
famili
address
possibl
broad
antivir
activ
may
relat
induct
interferon
examin
effect
compound
influenza
viru
replic
vero
cell
produc
interferon
observ
similar
level
inhibit
cell
data
shown
therebi
exclud
possibl
influenza
pandem
caus
viru
avian
origin
could
potenti
caus
million
death
worldwid
could
also
affect
poultri
industri
crucial
product
eggderiv
vaccin
primari
concern
need
address
prepar
next
influenza
epidem
pandem
abil
manufactur
produc
enough
dose
vaccin
suscept
popul
avail
antivir
compound
effect
prevent
influenza
viru
infect
luciferasebas
highthroughput
screen
compound
known
biolog
activ
identifi
uniqu
compound
least
reduct
luciferas
activ
compound
increas
luciferas
activ
least
fold
reason
compound
found
suppress
influenza
viru
replic
potenti
antiinfluenza
viru
drug
wherea
enhanc
influenza
replic
could
use
tool
boost
growth
vaccin
virus
tissu
cultur
moreov
biolog
target
compound
known
also
provid
clue
cellular
pathway
compon
crucial
influenza
viru
replic
use
antivir
drug
target
cellular
protein
also
advantag
current
drug
target
viral
protein
resist
far
like
develop
particular
interest
find
sodium
channel
inhibitor
sodium
channel
open
oppos
effect
viral
replic
ad
amilorideanalogu
inhibit
epitheli
na
channel
enac
na
ca
exchang
channel
kleyman
crago
could
enhanc
viral
replic
influenza
viru
fold
direct
contrast
use
sodium
channel
open
nontox
concentr
could
decreas
titer
influenza
viru
effect
compound
influenza
b
viru
replic
modest
fold
increas
decreas
overal
trend
similar
suggest
cellular
pathway
affect
compound
import
influenza
b
virus
fact
influenza
viru
shown
inhibit
amiloridesensit
sodium
channel
upon
infect
chen
et
al
kunzelmann
et
al
suggest
creat
cellular
environ
conduc
viral
replic
one
specul
addit
chemic
na
channel
inhibitor
phenamil
prior
infect
creat
preoptim
condit
therebi
boost
viru
replic
term
mechan
action
data
indic
increas
intracellular
na
concentr
caus
open
sodium
channel
lead
declin
influenza
viru
titer
wherea
decreas
intracellular
na
concentr
caus
inhibit
sodium
channel
boost
viral
replic
howev
differ
intracellular
ion
current
tightli
link
one
anoth
investig
requir
evalu
contribut
ca
due
regul
na
ca
exchang
channel
mani
compound
target
one
type
channel
difficult
attribut
effect
viru
replic
specif
channel
said
sever
amilorid
analogu
potent
activ
specif
channel
studi
show
slightli
stronger
provir
activ
phenamil
comparison
report
potenc
enac
na
ca
exchang
channel
indic
phenamil
specif
enac
specif
na
ca
exchang
channel
kleyman
crago
also
test
anoth
amilorid
analogu
compar
less
effect
enhanc
viru
replic
less
potent
activ
na
ca
exchang
channel
kleyman
crago
therefor
appear
abil
enhanc
growth
influenza
viru
correl
strength
inhibit
na
ca
exchang
channel
note
contrast
find
amilorid
deriv
report
inhibit
replic
sever
rna
virus
human
immunodefici
viru
human
rhinoviru
gazina
et
al
coxsackieviru
harrison
et
al
coronavirus
wilson
et
al
ewart
et
al
coronavirus
hepat
c
viru
premkumar
et
al
dengu
viru
premkumar
et
al
compound
shown
act
inhibit
format
viral
ion
channel
evid
influenza
viru
ion
channel
activ
advers
affect
amilorid
result
rather
show
influenza
viru
compound
provir
effect
possibl
effect
compound
viru
growth
due
chang
ion
transport
directli
rather
due
chang
cellular
activ
influenc
compound
exampl
pretreat
cell
compound
prior
infect
could
induc
either
proor
antiapoptot
state
influenc
viru
replic
howev
judg
caspas
activ
neither
inhibitori
enhanc
compound
found
exhibit
antior
proapoptot
effect
cell
time
infect
therefor
like
explan
observ
effect
compound
influenza
viru
replic
interestingli
shown
influenza
virusmedi
inhibit
na
channel
requir
pkc
activ
chen
et
al
kunzelmann
et
al
also
stimul
inhibit
na
transport
presenc
pkc
inhibitor
activ
respect
kunzelmann
et
al
data
correl
find
influenza
replic
inhibit
presenc
pkc
inhibitor
rottlerin
convers
enhanc
presenc
pkc
activ
pma
mezerein
influenza
viru
entri
requir
pkc
activ
believ
stimul
upon
bind
viru
cellular
receptor
arora
gass
root
et
al
rott
et
al
sieczkarski
et
al
howev
knowledg
first
demonstr
pkc
activ
enhanc
influenza
viru
growth
activ
pkc
also
found
regul
surfac
express
beta
gamma
subunit
enac
result
decreas
epitheli
na
reabsorpt
booth
stockand
stockand
et
al
therefor
appear
connect
activ
statu
pkc
transport
na
influenza
viru
replic
favor
presenc
activ
pkc
low
intracellular
na
concentr
also
demonstr
na
k
atpas
pump
inhibitor
ouabain
lanatosid
c
inhibit
replic
influenza
viru
ndv
vsv
repres
three
differ
rna
viru
famili
data
combin
result
previou
studi
show
inhibit
vaccinia
viru
mulv
sendai
viru
deng
et
al
dodson
et
al
nagai
et
al
tomita
kuwata
indic
cardioact
glycosid
broad
antivir
activ
use
vero
cell
determin
compound
act
induc
interferon
degre
viru
inhibit
observ
cell
seen
cell
one
common
featur
share
virus
possess
lipid
envelop
howev
data
ouabainmedi
inhibit
indic
act
postentri
stage
viral
life
cycl
dodson
et
al
main
function
na
k
atpas
pump
pump
na
cell
k
cell
maintain
cell
potenti
drive
forc
sever
membran
transport
protein
eg
na
glucos
symport
na
amino
acid
symport
na
hydrogen
antiport
gradient
also
import
remov
ca
na
ca
exchang
channel
thu
presenc
inhibitor
ouabain
increas
intracellular
na
concentr
well
ca
concentr
probabl
similar
effect
sodium
channel
open
also
inhibit
influenza
viru
replic
whether
compound
share
mechan
action
antivir
activ
subject
futur
research
studi
shown
influenza
virus
sensit
chang
intracellular
ion
concentr
may
suitabl
target
novel
antivir
drug
similarli
knowledg
crucial
factor
requir
optim
viru
growth
may
also
use
boost
viru
product
demonstr
use
pkc
activ
na
channel
inhibitor
technolog
could
use
product
influenza
viru
vaccin
like
make
transit
vitro
cultur
system
near
futur
demonstr
potenti
applic
would
requir
activ
wide
rang
influenza
virus
use
enhanc
compound
identifi
studi
boost
replic
differ
influenza
virus
influenza
b
viru
fdaapprov
vaccin
viru
strain
identif
viral
inhibitor
enhanc
valid
function
highthroughput
screen
assay
rais
possibl
find
novel
antivir
provir
drug
screen
librari
uncharacter
small
molecular
weight
molecul
summari
use
highthroughput
screen
biolog
activ
compound
shown
influenza
viru
growth
modul
posit
neg
chemic
manipul
na
transport
pkc
activ
find
provid
insight
cellular
pathway
involv
influenza
viru
replic
first
time
demonstr
feasibl
use
provir
drug
enhanc
growth
influenza
viru
vaccin
tissu
cultur
strong
inhibit
defin
reduct
luminesc
medium
inhibit
reduct
increas
luminesc
least
fold
classifi
enhanc
cell
infect
either
b
presenc
na
channel
open
rottlerin
pkc
inhibitor
viral
titer
determin
hour
post
infect
plaqu
assay
mdck
cell
assay
perform
triplic
present
mean
standard
deviat
student
test
p
p
cell
infect
influenza
viru
presenc
na
channel
inhibitor
nm
phenamil
b
pkc
activ
nm
mezerein
nm
pma
viral
titer
measur
hour
post
infect
plaqu
assay
mdck
cell
assay
perform
triplic
present
mean
standard
deviat
student
test
p
p
refer
data
point
mezerein
b
refer
data
point
phenamil
pma
b
cell
infect
influenza
viru
presenc
nm
na
channel
inhibitor
nm
mezerein
pkc
activ
viral
titer
measur
hour
post
infect
plaqu
assay
mdck
cell
assay
perform
triplic
present
mean
standard
deviat
student
test
p
p
p
refer
data
point
refer
data
point
mezerein
assay
perform
triplic
present
mean
standard
deviat
student
test
p
p
cell
infect
influenza
viru
presenc
nm
viral
titer
determin
hour
post
infect
plaqu
assay
mdck
cell
assay
perform
triplic
present
mean
standard
deviat
student
test
p
z
standard
deviat
neg
control
standard
deviat
posit
control
mean
signal
neg
control
infect
cell
mean
signal
posit
control
mock
infect
cell
b
cv
coeffici
variat
